A Risk-Predictive Model for Invasive Pulmonary Aspergillosis in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Yu Gu  
Nanjing Medical University  
https://orcid.org/0000-0001-7249-0174

Xianping Ye  
Nanjing Medical University

Yuxiu Liu  
Southern Medical University

Yu Wang  
Nanjing University Medical School

Kunlu Shen  
Southern Medical University

Jinjin Zhong  
Nanjing University Medical School

Bilin Chen  
Nanjing University Medical School

Xin Su (✉ suxinjs@163.com)  
Nanjing Jinling Hospital: East Region Military Command General Hospital

Research

Keywords: IPA, AECOPD, risk factors, nomogram, model

DOI: https://doi.org/10.21203/rs.3.rs-254758/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Objectives: Invasive pulmonary aspergillosis (IPA) is increasingly reported in chronic obstructive pulmonary disease (COPD) patients. These patients often have poor clinical outcomes. Early recognition of IPA in COPD is always challenging. We aimed to develop and validate a risk model using readily available clinical parameters to predict IPA for acute exacerbation of COPD (AECOPD) patients.

Methods: We performed a retrospective cohort study. AECOPD patients who were admitted to Jinling Hospital between January 2012 and December 2017 were included. 880 AECOPD patients were randomly divided into the training set (70%, n = 616) and validation set (30%, n = 264). A nomogram model was developed using multivariate logistic regression from training set. The discrimination and calibration of model were validated internally. Decision curve analyses assessed the clinical utility of the nomogram.

Results: The incidence of IPA in hospitalized AECOPD patients was 9.6% in the training set (59 cases of IPA) and 9.1% in the validation set (24 cases of IPA), respectively. The nomogram model consisted of independent factors associated with IPA included lung function GOLD III-IV, utility of broad-spectrum antibiotic over 10 days in the last month, oral or intravenous corticosteroids (prednisone) over 265 mg in the last 3 months and serum albumin<30g/L. The model performed good discrimination and calibration in validation set (c-statistic, 0.79 [95%CI, 0.68-0.90]). The 95%CI region of calibration belt did not cross the 45-degree diagonal bisector line ($P = 0.887$).

Conclusion: The simple risk predictive model for earlier recognition of IPA is useful in hospitalized AECOPD patients.

Background

Nowadays, chronic obstructive pulmonary disease (COPD) has been widely recognized as a major risk factor for invasive pulmonary aspergillosis (IPA)[1]. The current mortality rate is as high as 100% in untreated patients[2, 3]. Delayed diagnosis or delayed antifungal therapy are associated with increased mortality in patients with IPA[4, 5]. Early recognition of IPA represents an opportunity to improve clinical outcome. In fact, the diagnosis of IPA in COPD patients is difficult. One of the important reasons is that the clinical manifestations and imaging presentations are not specific. On the other hand, the current laboratory diagnostic tests are not very sensitive for non-neutropenic population including COPD patients, leading to delays in diagnosis and treatment of IPA [4, 6, 7].

Combination of risk factors, clinical manifestations, and laboratory tests results together, is the current strategy for IPA diagnosis. Fully revealing risk factors of IPA in COPD patients is important to help clinicians identify infection[8]. In recent years, it has been revealed that worse lung function (GOLD III or IV) and systematic usage of corticosteroid play a significant role in the development of IPA[1]. Studies have also shown that COPD patients who were admitted to ICU, had chronic heart failure, receiving antibiotic treatment longer than 10 days in the past 3 months are independent predictors of IPA in COPD
patients[3, 9]. The identification of one or more predisposing conditions would be critical to trigger further diagnostic exploration, which is a benefit to the early diagnosis and treatment.

There are multiple risk factors of IPA in COPD patients. But, few studies focused on the weight of each related risk factors. There is no Risk-Predictive scoring model of IPA currently. Therefore, it is necessary to further investigate the risk factors of IPA in COPD patients. It is of great importance for early diagnosis and treatment.

This study aims to identify the risk factors for IPA in hospitalized acute exacerbation of COPD (AECOPD) patients. Then, we develop and validate a risk-prediction model for rapid recognition and appropriate empirical antifungal treatment in severe AECOPD patients, especially in source limited hospitals.

**Methods**

**Data Source**

This retrospective single-center study was based on the clinical records of AECOPD patients retrieved from the Department of Respiratory and Critical Care Medicine of Jinling Hospital from January 2012 to December 2017.

*Training set and Validation set.* AECOPD patients fulfill with study design were enrolled into our study. We randomly assigned 70% cases into training set, and 30% cases into internal validation set.

**Participants**

We included patients with AECOPD and need hospitalization. The exclusion criteria were as follows: (1) Patients who were suffering from neutropenia (peripheral blood absolute neutrophils count less than 0.5×10⁹/L) or with hematological malignancy; (2) patients admitted to hospital without AECOPD; (3) patients with insufficient information. The diagnosis of AECOPD was based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines[10]. Bulpa criteria was applied to IPA diagnosis[1]. Therefore, Proven IPA was diagnosed by existence of mycelium and related tissue damage in histopathological examination of lung tissue and was accompanied by any of the following: (1) isolation of *Aspergillus* in the lower respiratory tract (LRT) samples; (2) positive serum *Aspergillus* antigen or antibody; (3) direct molecular immunology or culture methods observed that the mycelium was *Aspergillus* filaments. Probable IPA was diagnosed by the coexistence of host factors, clinical manifestations (COPD patients had a recent exacerbation of dyspnea and suggestive chest imaging, and poor response to regular treatment) and microbiological evidence (*Aspergillus* isolation in LRT sample or two consecutive positive serum galactomannan [GM] tests). Possible IPA required host factors, but without microbiological evidence. Colonization was defined as isolation of *Aspergillus* in LRT samples without symptom. In this study, Proven/probable IPA were taken as IPA; possible IPA with positive response to antifungal therapy were also considered as IPA.

**Risk Factors**
Data were collected from eligible AECOPD patients concerning potential risk factors for IPA. All risk factors were readily accessible from early current and past medical history, including demographic data, comorbidities, pulmonary function, pharmacological history (including oral or intravenous corticosteroids in the last 3 months and utility broad-spectrum antibiotic longer than 10 days in the last month), mechanical ventilation at admission and previous history of acute exacerbation. Detailed data were shown in Table 1.
| Characteristic                        | Training Set  | Validation Set | P   |
|--------------------------------------|---------------|----------------|-----|
|                                      | (n = 616)     | (n = 264)      |     |
| IPA                                  | 59 (9.6)      | 24 (9.1)       | 0.821 |
| Age, years                           | 75 ± 10.8     | 75 ± 10.6      | 0.936 |
| Gender male                          | 525 (85.2)    | 222 (84.1)     | 0.666 |
| Smoking index > 400                  | 113 (18.3)    | 59 (22.3)      | 0.170 |
| Comorbidities                        |               |                |     |
| Previous tuberculosis                | 37 (6)        | 21 (8)         | 0.286 |
| Lung cancer                          | 25 (4.1)      | 17 (6.4)       | 0.129 |
| Bronchiectasis                       | 8 (1.3)       | 7 (2.7)        | 0.163 |
| Asthma                               | 18 (2.9)      | 14 (5.3)       | 0.084 |
| Lobectomy surgery                    | 13 (2.1)      | 10 (3.8)       | 0.153 |
| Other solid tumor                    | 23 (3.7)      | 13 (4.9)       | 0.414 |
| Hypertension                         | 297 (48.2)    | 123 (46.6)     | 0.659 |
| Diabetes mellitus                    | 94 (15.3)     | 43 (16.3)      | 0.700 |
| Congestive heart failure             | 119 (19.3)    | 72 (27.3)      | 0.009 |
| Chronic and acute kidney disease     | 44 (7.1)      | 15 (5.7)       | 0.427 |
| Advanced liver disease               | 8 (1.3)       | 1 (0.4)        | 0.292 |
| Connective tissue disease            | 13 (2.1)      | 7 (2.7)        | 0.622 |

Abbreviations: IPA, invasive pulmonary aspergillosis; GOLD, global initiative for chronic obstructive lung disease; ICU, intensive care unit.

* Values are presented as numbers and percentages, unless otherwise indicated.

‡ This result was obtained from the hospital admission.

§ The GOLD stage was obtained from the latest pulmonary function test within the last year.
|                                      | No. (%) *                  |
|--------------------------------------|----------------------------|
| Serum albumin < 30g/L ‡              | 151 (24.5) 70 (26.5) 0.530 |
| GOLD III-IV §                        | 409 (66.4) 177 (67) 0.852  |
| Respiratory failure                  | 129 (20.9) 74 (28) 0.022   |
| Co-infection                         |                            |
| Lung bacterial infection             | 100 (16.2) 54 (20.5) 0.131 |
| Pulmonary tuberculosis               | 12 (19.5) 4 (1.6) 0.788    |
| Previous treatment                   |                            |
| Inhale corticosteroids               | 124 (20.1) 47 (17.8) 0.424 |
| Oral or intravenous corticosteroids  | 59 (9.6) 36 (13.6) 0.075   |
| Cytotoxic drug utility               | 2 (0.3) 4 (1.5) 0.070      |
| Broad-spectrum antibiotic > 10 days  | 45 (7.3) 28 (10.6) 0.104   |
| Invasive ventilator utility          | 49 (8) 28 (10.6) 0.202     |
| ICU admission 1 month prior          | 54 (8.8) 39 (14.8) 0.008   |
| Hospital acute exacerbation ≥ 2/year | 111 (18) 51 (19.3) 0.649   |

Abbreviations: IPA, invasive pulmonary aspergillosis; GOLD, global initiative for chronic obstructive lung disease; ICU, intensive care unit.

* Values are presented as numbers and percentages, unless otherwise indicated.

‡ This result was obtained from the hospital admission.

§ The GOLD stage was obtained from the latest pulmonary function test within the last year.

**Statistical Analysis**

Statistical analysis was performed using statistical software SPSS (version 25.0, Chicago, IL, USA) and R software (version 3.5.2). Data were expressed as mean ± standard deviation (SD) or median (interquartile IQR) for continuous variables, whereas categorical variables were summarized as counts (percentage). Differences between patients in training and validation set, and between patients with and without IPA in the training set were explored using χ² or Fisher exact test for categorical variables, t test for normally distributed continuous variables and Mann-Whitney U test for abnormally distributed variables. Variables with P < 0.05 in univariate analysis of training set were substituted into multivariate analysis. We then implemented multivariate logistic regression analysis based on backward stepwise likelihood-ratio
method, setting a $P$ value $< 0.05$ for the inclusion of variables. A nomogram of risk-predictive model for IPA was developed from the regression purposeful variable by library ‘rms’ in R[11]. Patients in the internal validation set were used for assessing the discrimination and calibration of the nomogram. The discriminative ability was measured using the area under the ROC curve (AUC), which known as the c-statistic. Calibration of the model was assessed by comparison of the predicted and observed probability of IPA[12]. The fit of the scoring model was evaluated by the Hosmer-Lemeshow goodness-of-fit test. Decision curve analysis was performed according to van Calster et al to assess the clinical utility of the nomogram, using the library ‘rmda (risk model decision analysis)’ in R[13]. Unless stated otherwise, a two-tailed $P$ value $< 0.05$ was considered statistically significant.

**Results**

We screened 1277 hospitalized patients primarily diagnosed as AECOPD. 397 patients were excluded for the following reasons: neutropenia (n = 1); *Aspergillus* colonization (n = 10); not real AECOPD (n = 298); insufficient clinical data (n = 82). 83 cases were diagnosed as IPA (9.4%), with an average age of 75.2 ± 10.7 (40–101 years old). The training set was consisted of 616 patients (IPA group 59 cases, non-IPA group 557 cases), and the validation set was consisted of 264 patients (IPA group 24 cases, non-IPA group 240 cases). Among all the IPA patients, 13 cases were diagnosed with proven IPA, 60 cases with probable IPA (20 cases with positive culture results of *Aspergillus* in the LRT specimens, 25 cases with two consecutive positive serum GM and 3 cases for positive bronchoalveolar lavage fluid (BALF) GM tests, 10 cases with positive results in both sputum culture and serum GM, 2 cases for positive results in BALF GM tests and the sputum test), and 10 cases with possible IPA all had positive response to antifungal therapy. The flow chart shows the strategy to identify the participants of the AECOPD cohort (Supplementary Figure S1). The demographic and clinical characteristics of patients in the training set and validation set are listed in Table 1. The IPA incidence was comparable between two data sets (9.6% vs 9.1%; $P = 0.821$).

The characteristics of AECOPD patients with and without IPA in training set were summarized in Table 2. There was no difference in each group of co-infection including pulmonary tuberculosis. But, two groups varied from each other in terms of treatment before or after patients admitted to the ward, such as oral or intravenous corticosteroids in the last 3 months, utility broad-spectrum antibiotic longer than 10 days in last month, invasive ventilator utility and ICU admission in previous 30 days. Table 2 showed that IPA group had a significant difference with non-IPA in terms of 8 factors, including hypertension, serum albumin < 30g/L, lung function GOLD $\geq$ II, utility broad-spectrum antibiotic longer than 10 days in last month and so on.
| Characteristic                              | No. (%) *                          | P       |
|--------------------------------------------|------------------------------------|---------|
| **IPA (n = 59)**                           | **Non-IPA (n = 557)**              |         |
| Age, years                                 |                                    |         |
| Median(range)                              | IPA 72 (67, 82) Non-IPA 76 (68, 84) | 0.08    |
| Male gender                                | IPA 55 (93.2) Non-IPA 470 (84.4)   | 0.69    |
| Smoking index > 400                        | IPA 16 (27.1) Non-IPA 97 (17.4)    | 0.07    |
| Comorbidities                              |                                    |         |
| Previous tuberculosis                      | IPA 6 (10.2) Non-IPA 31 (5.6)      | 0.15    |
| Lung cancer                                | IPA 4 (6.8) Non-IPA 21 (3.8)       | 0.29    |
| Bronchiectasis                             | IPA 1 (1.7) Non-IPA 7 (1.3)        | 0.78    |
| Asthma                                     | IPA 1 (1.7) Non-IPA 17 (3.1)       | 0.56    |
| Lobectomy surgery                          | IPA 1 (1.7) Non-IPA 12 (2.2)       | 0.82    |
| Other solid tumor                          | IPA 0 (0) Non-IPA 23 (4.1)         | 0.11    |
| Hypertension                               | IPA 21 (35.6) Non-IPA 276 (49.6)   | 0.04    |
| Diabetes mellitus                          | IPA 7 (11.9) Non-IPA 87 (15.6)     | 0.44    |
| Congestive heart failure                   | IPA 13 (22) Non-IPA 106 (19)       | 0.57    |
| Chronic and acute kidney disease           | IPA 4 (6.8) Non-IPA 40 (7.2)       | 0.96    |
| Advanced liver disease                     | IPA 2 (3.4) Non-IPA 6 (1.1)        | 0.14    |
| Connective tissue disease                  | IPA 0 (0) Non-IPA 13 (2.3)         | 0.24    |
| Laboratory results                         |                                    |         |
| Serum albumin < 30g/L                      | IPA 29 (49.2) Non-IPA 122 (21.9)   | < 0.01  |
| GOLD III-IV                                | IPA 56 (94.9) Non-IPA 353 (63.4)   | < 0.01  |
| Respiratory failure                        | IPA 13 (22) Non-IPA 116 (20.8)     | 0.83    |
| Co-infection                               |                                    |         |
| Lung bacterial infection                    | IPA 10 (16.9) Non-IPA 90 (16.2)    | 0.88    |

Abbreviations: IPA, invasive pulmonary aspergillosis; GOLD, global initiative for chronic obstructive lung disease; ICU, intensive care unit.

* Values are presented as numbers and percentages, unless otherwise indicated.
| Characteristic                              | IPA (n = 59) | Non-IPA (n = 557) | P     |
|--------------------------------------------|--------------|-------------------|-------|
| Pulmonary tuberculosis                      | 0 (0)        | 12 (2.2)          | 0.25  |
| Previous treatment                         |              |                   |       |
| Inhale corticosteroids                     | 11 (18.6)    | 113 (20.3)        | 0.76  |
| Oral or intravenous corticosteroids        | 18 (30.5)    | 41 (7.4)          | < 0.01|
| Cytotoxic drug utility                     | 0 (0)        | 2 (0.4)           | 0.64  |
| Broad-spectrum antibiotic >10 days         | 17 (28.8)    | 28 (5)            | < 0.01|
| Invasive ventilator utility                | 9 (15.3)     | 40 (7.2)          | 0.03  |
| ICU admission 1 month prior                | 10 (16.9)    | 44 (7.9)          | 0.02  |
| Hospital acute exacerbation ≥ 2/year       | 20 (33.9)    | 91 (16.3)         | < 0.01|

Abbreviations: IPA, invasive pulmonary aspergillosis; GOLD, global initiative for chronic obstructive lung disease; ICU, intensive care unit.

* Values are presented as numbers and percentages, unless otherwise indicated.

It’s worth noting that oral or intravenous corticosteroids in the last 3 months before admission was of statistical significance between the IPA and non-IPA groups. Therefore, we examined the cumulative dose of corticosteroids during the patients’ treatment 90 days before their admission and found that 59 out of 616 patients used corticosteroids systematically during the last 90 days. All corticosteroids cumulative dose was calculated on prednisone equivalent basis (0.75 mg of dexamethasone, 4 mg of methylprednisolone or 20 mg of hydrocortisone is equivalent to 5 mg of prednisone). 18 out of 59 patients in IPA group, with a mean cumulative dose of prednisone 718 mg (range, 120-2050mg), 41 out of 59 patients in non-IPA group, with a mean cumulative dose of prednisone 307 mg (range, 75-1800mg) in this study. The ROC curve is shown in figure S2 (Supplementary), the area under the ROC curve was 0.75 (95% CI, 0.62–0.88;P = 0.002). The cut-off cumulative dose of prednisone for the risk of IPA was 265 mg, with a sensitivity of 66.7% and specificity 75.6%.

**Nomogram Development**

The multivariate logistic regression model considered 8 parameters with P value < 0.05, including hypertension, serum albumin < 30g/L, GOLD III-IV, oral or intravenous corticosteroids, utility broad-spectrum antibiotic longer than 10 days in last month, invasive ventilator utility, ICU admission 1 month previously and hospital acute exacerbation ≥ 2/year. Multivariate logistic analysis showed four independent risk-predictive factors for IPA: lung function GOLD III-IV, oral or intravenous corticosteroids (prednisone) ≥ 265 mg in the last 3 months, utility broad-spectrum antibiotic longer than 10 days in last
month, and serum albumin < 30g/L (Table 3). According to multivariate regression results, the nomogram was generated based on the contributed weights of factors in the training set to calculate the risk of IPA (Fig. 1). In the nomogram, each factor has a related score for its contribution to IPA.

| Variable | β coefficient | Wald | OR (95%CI) | P       |
|----------|---------------|------|------------|---------|
| Serum albumin < 30g/L | 0.8 | 6.7 | 2.23 (1.22 to 4.1) | 0.01 |
| GOLD III-IV | 2.06 | 11.2 | 7.87 (2.35 to 26.35) | 0.001 |
| Dose ≥ 265 mg * | 2.34 | 20.48 | 10.36 (3.76 to 28.53) | < 0.001 |
| Broad-spectrum antibiotic > 10 days | 1.56 | 16.81 | 4.77 (2.26 to 10.07) | < 0.001 |

Table 3
Multivariate Logistic Regression for IPA in the Training Set

Abbreviations: OR, odds ratio; CI, confidence interval; Ref, reference variable; GOLD, global initiative for chronic obstructive lung disease.

* Oral or intravenous corticosteroids (prednisone) ≥ 265mg last 3 months.

**Discrimination and Calibration**

The c-statistic of the nomogram was 0.8 (95%CI, 0.74–0.86) in the training set data (Fig. 2, blue curve), and 0.79 (95%CI, 0.68–0.90) in the validation set (Fig. 2, red curve). The calibration belt suggested that the nomogram had strong concordance performance in both the training and validation data sets (Fig. 3a, 3b). The 95%CI region of GiViTI calibration belt did not cross the 45-degree diagonal bisector line both in two data sets (P = 0.722, P = 0.887; respectively). The model showed good fit between predicted and observed probabilities because the P value for the Hosmer-Lemeshow test was both more than 0.05 in the training set and validation set (P = 0.69, P = 0.70; respectively).

**Decision Curve Analysis**

Decision curve analysis results of the risk nomogram in the training set and validation set were shown to determine an optimal decision point of the nomogram (Supplementary Figure S3). For predicted risk thresholds between 0% and 53%, the nomogram model showed a positive net benefit in two data sets.
Discussion

IPA in the context of COPD is attracting more and more attention. Current studies have reported that the incidence rate of IPA in COPD stands between 1.3% and 16.13%[7, 14]. This cohort study involved a large population of AECOPD patients, revealing the incidence and mortality of IPA, as well as the risk factors of developing IPA. Furthermore, our study shows a 9.4% incidence of IPA in hospitalized AECOPD patients, which was at a relatively high level. Multiple reasons might lead to such a high incidence. First, our hospital locates in sub-tropical regions of Asia, where environmental fungi grow well due to the temperature and humidity, that might lead to a higher incidence of fungal infection. Second, patients suspected with pulmonary aspergillosis in these regions prefer to transfer to our department, which is a regional center for diagnosis and treatment of pulmonary mycosis.

Patients with AECOPD are often treated with corticosteroids. Current studies prove that corticosteroid is one of the independent risk factors for IPA in COPD[1], but there is no consensus on the cutoff value of accumulative dose of corticosteroids, especially in patients with COPD. Stuck et al, reported that corticosteroids rarely lead to a serious infection in patients with equivalent prednisone dose less than 10mg/day or a cumulative dose less than 700mg[15]. The EORTC/MSG Consensus Group definite prolonged use of prednisone at a mean minimum dose of 0.3 mg/kg/day for > 3 weeks as a host factor for invasive fungal disease[16]. However, the study above was not focused on patients with COPD, and whether the cutoff value of cumulative dose of corticosteroids is suitable for COPD patients remained undetermined. Our study showed that the cumulative dose of systemic prednisone over 265mg in the last 3 months may lead to IPA in hospitalized AECOPD patients, with a sensitivity of 66.7% and specificity of 75.6%. Our study indicates that inpatients with AECOPD may develop IPA even in a low dose of steroids. Besides, cases of IPA have even been reported in patients with long term inhaled high dose of steroids[17, 18].

The existing reports believed that early identification of IPA is essential for early IPA diagnosis and timely treatment[19, 20]. In this regard, our study has made some clinical implications in the rapid identification of patients with high-risk IPA. The study also found that combined poor lung function (GOLD III-IV), serum albumin < 30g/L and utility broad-spectrum antibiotic longer than 10 days in last month are also independent risk factors for IPA in patients with AECOPD. To our best knowledge, we innovate to develop a simple nomogram for predicting risk of IPA in AECOPD patients. The good discriminative and calibrated ability of the predictive model is found in the internal validation cohort.

Our study had some limitations. First, this study was a single-center retrospective study and we only did internal validation to evaluate the discrimination and calibration of the scoring model. Multicenter prospective studies should be conducted to externally validate the results. Second, the binary result (positive/negative) used to classify COPD co-morbidities cannot reflect the severity of the combined disease. Severity classifying of the comorbidities might add the value of the results.

In conclusion, the nomogram model, which is consisted of four independent risk factors for IPA, may empower clinicians and AECOPD patients with earlier, more accurate information regarding the risk of...
IPA. Further studies are needed to validate the application of the nomogram in clinical practice to determine whether IPA can be better predicted.

**Abbreviations**

IPA: invasive pulmonary aspergillosis; COPD: chronic obstructive pulmonary disease; AECOPD: acute exacerbation of chronic obstructive pulmonary disease; ICU: intensive care unit; GOLD: Global Initiative for Chronic Obstructive Lung Disease; LRT: lower respiratory tract; GM: galactomannan; SD: standard deviation; IQR: interquartile; AUC: area under the ROC curve; BALF: bronchoalveolar lavage fluid; EORTC/MSG: European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.

**Declarations**

**Acknowledgements:**

Not applicable.

**Authors’ contributions:**

Xin Su, Yu Gu, Xianping Ye and Yuxiu Liu are the guarantor of the manuscript and take responsibility for the content of this manuscript. Xin Su, Yu Gu, Xianping Ye and Yuxiu Liu contributed to the design of the study; Yu Gu, Xianping Ye, Yuxiu Liu, Yu Wang and Kunlu Shen were involved in the data analysis; Yu Gu, Xianping Ye and Yuxiu Liu wrote the initial draft of the manuscript, and the remaining authors were involved in revising the manuscript; Jinjin Zhong and Bilin Chen contributed to the acquisition of primary data; Xin Su provided guidance for implementation and completion of the study. All authors read and approved the final manuscript.

**Funding:**

This work was supported by the Project of Natural Science Foundation of China [Grant number 82070011, 81873400], the Key Project of Jiangsu Commission of Health (K2019004), and “333 project” of Jiangsu Province (BRA2019339).

**Availability of data and materials:**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate:**

The study protocol was approved by the Institute Ethics Committee of Jinling Hospital (2012NJKY-035-02). The study protocol conformed to the ethical guidelines of the 1975 Helsinki Declaration.
Consent for publication:

Not applicable.

Competing interests:

The authors declare that they have no competing interests.

References

1. Bulpa P, Dive A, Sibille Y: **Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease.** *Eur Respir J* 2007, **30:**782-800.

2. Denning DW: **The ambitious '95-95 by 2025' roadmap for the diagnosis and management of fungal diseases.** *Thorax* 2015, **70:**613-614.

3. Ader F, Nseir S, Le Berre R, Leroy S, Tillie-Leblond I, Marquette CH, Durocher A: **Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen.** *Clin Microbiol Infect* 2005, **11:**427-429.

4. Patel DA, Gao X, Stephens JM, Forshag MS, Tarallo M: **US hospital database analysis of invasive aspergillosis in the chronic obstructive pulmonary disease non-traditional host.** *J Med Econ* 2011, **14:**227-237.

5. Russo A, Falcone M, Vena A, Venditti C, Mancini C, Morelli A, Venditti M: **Invasive pulmonary aspergillosis in non-neutropenic patients: analysis of a 14-month prospective clinical experience.** *J Chemother* 2011, **23:**290-294.

6. Xu H, Li L, Huang WJ, Wang LX, Li WF, Yuan WF: **Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case control study from China.** *Clin Microbiol Infect* 2012, **18:**403-408.

7. Guinea J, Torres-Narbona M, Gijon P, Munoz P, Pozo F, Pelaez T, de Miguel J, Bouza E: **Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome.** *Clin Microbiol Infect* 2010, **16:**870-877.

8. Benedict K, Richardson M, Vallabhaneni S, Jackson BR, Chiller T: **Emerging issues, challenges, and changing epidemiology of fungal disease outbreaks.** *Lancet Infect Dis* 2017, **17:**e403-e411.

9. Bassetti M, Righi E, De Pascale G, De Gaudio R, Giarratano A, Mazzei T, Morace G, Petrosillo N, Stefani S, Antonelli M: **How to manage aspergillosis in non-neutropenic intensive care unit patients.** *Crit Care* 2014, **18:**458.

10. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al: **Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.** *Am J Respir Crit Care Med* 2013, **187:**347-365.
11. Bursac Z, Gauss CH, Williams DK, Hosmer DW: **Purposeful selection of variables in logistic regression.** *Source Code Biol Med* 2008, **3**:17.

12. Nattino G, Finazzi S, Bertolini G: **A new test and graphical tool to assess the goodness of fit of logistic regression models.** *Stat Med* 2016, **35**:709-720.

13. Van Calster B, Wynants L, Verbeek JFM, Verbakel JY, Christodoulou E, Vickers AJ, Roobol MJ, Steyerberg EW: **Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators.** *Eur Urol* 2018, **74**:796-804.

14. Guinea J, Jensen J, Pelaez T, Gijon P, Alonso R, Rivera M, Munoz P, Bouza E: **Value of a single galactomannan determination (Platelia) for the diagnosis of invasive aspergillosis in non-hematological patients with clinical isolation of Aspergillus spp.** *Med Mycol* 2008, **46**:575-579.

15. Stuck AE, Minder CE, Frey FJ: **Risk of infectious complications in patients taking glucocorticosteroids.** *Rev Infect Dis* 1989, **11**:954-963.

16. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH, et al: **Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.** *Clin Infect Dis* 2019.

17. Palmer LB, Greenberg HE, Schiff MJ: **Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease.** *Thorax* 1991, **46**:15-20.

18. Leav BA, Fanburg B, Hadley S: **Invasive pulmonary aspergillosis associated with high-dose inhaled fluticasone.** *N Engl J Med* 2000, **343**:586.

19. Schelenz S, Barnes RA, Barton RC, Cleverley JR, Lucas SB, Kibbler CC, Denning DW, British Society for Medical M: **British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases.** *Lancet Infect Dis* 2015, **15**:461-474.

20. Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Florl C, Lewis RE, Munoz P, Verweij PE, et al: **Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.** *Clin Microbiol Infect* 2018, **24** Suppl 1:e1-e38.